Sentrimed is a clinical stage biotechnology company developing novel targeted therapies that harness critical cell-to-cell communication processes essential to reviving the body’s ability to recognize, contain and eliminate abnormal cells found in cancer and potentially malignant disorders. Sentrimed is a leader in contact normalization, a cellular communication process that enables normal cells to inhibit tumor growth and migration, and trigger targeted tumor cell destruction.
Sentrimed is developing a dynamic pipeline based on the seminal research of our scientific team. Sentrimed founder Dr. Gary Goldberg has been performing internationally recognized research on cell-to-cell communication and contact normalization for decades. Together with our scientific board members, they have made significant discoveries to further advance the understanding of the pivotal role that contact normalization plays in the body’s ability to contain and eliminate tumor cells.
